Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib

NCT01774344 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01774344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01774344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
May 14, 2013
Completion date
July 5, 2019
Enrollment
573 (actual)
Sites
147

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular